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Abstract
Background: Pro-inflammatory cytokines can affect intracellular lipid metabolism. A variety of
effects have been described for different cell types; hepatocyte lipid turnover pathways are
inhibited during inflammation, whereas interleukin-1β (IL-1β) reduces intracellular cholesterol
levels in fibroblasts. Levels of the pro-inflammatory cytokines IL-1β and tumour necrosis factor-α
(TNF-α) are up-regulated at sites of formation of atherosclerotic plaques. Plaque formation is
though to begin with infiltration of monocytes to the intimal layer of the vascular wall, followed by
differentiation to macrophages and macrophage uptake of modified lipoproteins, resulting in
accumulation of intracellular lipids. The lipid-filled cells are referred to as macrophage foam cells,
a key feature of atherosclerotic plaques. We have investigated the effects of IL-1β and TNF-α on
macrophage foam cells in order to assess whether presence of the pro-inflammatory cytokines
improves or aggravates macrophage foam cell formation by affecting lipid accumulation and lipid
turn-over in the cells.
Results: Differentiated primary human macrophages or THP-1 cells were lipid loaded by uptake
of aggregated low density lipoproteins (AgLDL) or very low density lipoproteins (VLDL), and then
incubated with IL-1β (0 – 5000 pg/ml) in lipoprotein-free media for 24 h. Cells incubated in absence
of cytokine utilized accumulated neutral lipids, in particular triglycerides. Addition of exogenous IL-
1β resulted in a dose-dependent retention of intracellular cholesterol and triglycerides. Exchanging
IL-1β with TNF-α gave a similar response. Analysis of fatty acid efflux and intracellular fatty acid
activation revealed a pattern of decreased lipid utilization in cytokine-stimulated cells.
Conclusion: IL-1β and TNF-α enhance macrophage foam cell formation, in part by inhibition of
macrophage intracellular lipid catabolism. If present in vivo, these mechanisms will further augment
the pro-atherogenic properties of the two cytokines.
Background
Human lipid and lipoprotein metabolism is altered dur-
ing acute phase response. A striking example is sepsis
(endotoxinemia), which is correlated with severe hyper-
triglyceridemia. In cells such as hepatocytes, smooth mus-
cle cells, and adipocytes several effects of endotoxins on
intracellular lipid metabolism are identical to, or medi-
ated by, effects of pro-inflammatory cytokines such as
interleukin-1β (IL-1β) and tumour necrosis factor-α
(TNF-α) [1]. These two cytokines are also present in
atherosclerotic plaques, where it has been suggested that
the cytokines mediate a constant low-grade inflammatory
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state. If they affect lipid metabolism in cells in the vascular
wall in a similar manner as they affect peripheral tissues
during acute phase response, such effects may contribute
to atherosclerotic plaque development.
Macrophage foam cells are a characteristic feature of
atherosclerotic plaques. During foam cell formation mod-
ified lipoproteins enters cells by receptor mediated uptake
and excess neutral lipids are stored as lipid droplets, creat-
ing a typical foamy appearance. Oxidized forms of low
density lipoproteins (LDL) are the modified lipoprotein
usually considered causative during foam cell formation
in vivo, but excessive uptake of other lipoproteins can also
result in intracellular lipid accumulation and give macro-
phages a foamy appearance. We have previously described
an in vitro model system for foam cell formation, where
cells are lipid loaded by incubation with aggregated LDL
(AgLDL) or very low density lipoproteins (VLDL). In this
in vitro model system all cells incubated with AgLDL or
VLDL have large numbers of intracellular lipid droplets,
illustrating a model for macrophage foam cell formation
with predominantly cholesterol ester or triglyceride rich
lipid droplets, respectively [2].
We hypothesised that IL-1β and TNF-α affect lipid turno-
ver in macrophage foam cells, a mechanism not previ-
ously described for this cell type. After lipid loading, foam
cells were treated with either cytokine, mimicking the in
vivo situation where atherosclerosis development is prop-
agated by both hyperlipidemia and inflammation.
Results
Intracellular lipid content of macrophage foam cells
Isolated primary human monocytes were differentiated to
macrophages and lipid loaded by incubation with VLDL
or AgLDL. Control cells were incubated for the same
period of time in lipoprotein-free cell culture media. After
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Lipid content of primary human macrophage incubated with  IL-1β Figure 1
Lipid content of primary human macrophage incu-
bated with IL-1β. Cells were differentiated for four days 
with GM-CSF, and then incubated for 24 h in absence or 
presence of lipoproteins (50 μg/ml), rinsed with heparin and 
incubated with IL-1β in lipoprotein-free media for an addi-
tional 24 h. Intracellular lipids were extracted and lipid values 
normalized to cell protein content. A. Triglyceride content of 
VLDL treated cells, B. Triglyceride content of control or 
AgLDL treated cells, C. Cholesterol content of cells. Data 
represents mean ± SEM (n = 6) for a representative experi-
ment repeated three times with cells from different donors. * 
= P < 0.05, ** = P < 0.01 compared to cells incubated in 
absence of IL-1β. Diamonds = control cells (no lipoprotein 
lipid loading), squares = AgLDL, triangles = VLDL.BMC Immunology 2008, 9:70 http://www.biomedcentral.com/1471-2172/9/70
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incubation in presence or absence of lipoproteins all cells
were rinsed with heparin in order to remove lipoproteins
attached to the cell surface. Fresh cell culture media sup-
plemented with 0–5000 pg cytokine/ml was added to
cells and the macrophages were incubated in this media
for an additional 24 h. Cell viability was not affected by
this treatment, as judged by two different assays per-
formed both directly after lipoprotein lipid loading and
after subsequent cytokine treatment.
Incubation of control macrophages and macrophage
foam cells with IL-1β resulted in higher levels of intracel-
lular lipids in cytokine treated cells, in a cytokine dose-
dependent manner. Effects were most pronounced in cells
lipid loaded by incubation with VLDL before cytokine
treatment (Fig. 1A and 1C). The same pattern was appar-
ent in control cells and cells incubated with AgLDL before
cytokine treatment (Fig. 1B and 1C). Experiments were
repeated with TNF-α replacing IL-1β. TNF-α induced a
dose-dependent increase in intracellular triglyceride levels
of control and AgLDL treated cells, whereas there was a
limited effect of TNF-α on VLDL treated cells (Fig. 2A and
2B). TNF-α had no strong effect on intracellular choles-
terol levels neither in lipid loaded nor in control cells (Fig.
2C).
The experiments were repeated using the human leukae-
mia cell line THP-1. In this cell type TNF-α displayed a
strong and significant effect on intracellular lipid levels in
lipid loaded cells as well as in control cells. Exposure to
the cytokine resulted in high levels of intracellular triglyc-
eride and total cholesterol regardless of lipid loading
before cytokine treatment (Fig. 3). The same was apparent
after incubation of THP-1 cells with IL-1β (Fig. 4).
Included in Fig. 4 are intracellular lipid levels directly after
lipoprotein lipid loading, i.e. before exposure to cytokine.
Incubation of lipid loaded cells with 5000 pg IL-1β/ml,
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Lipid content of primary human macrophage incubated with  TNF-α Figure 2
Lipid content of primary human macrophage incu-
bated with TNF-α. Cells were differentiated for four days 
with GM-CSF, and then incubated for 24 h in absence or 
presence of lipoproteins (50 μg/ml), rinsed with heparin and 
incubated with TNF-α in lipoprotein-free media for an addi-
tional 24 h. Intracellular lipids were extracted and lipid values 
normalized to cell protein content. A. Triglyceride content of 
VLDL treated cells, B. Triglyceride content of control or 
AgLDL treated cells, C. Cholesterol content of cells. Data 
represents mean ± SEM (n = 6) for a representative experi-
ment repeated three times with cells from different donors. * 
= P < 0.05, ** = P < 0.01 compared to cells incubated in 
absence of IL-1β. Diamonds = control cells (no lipoprotein 
lipid loading), squares = AgLDL, triangles = VLDL.BMC Immunology 2008, 9:70 http://www.biomedcentral.com/1471-2172/9/70
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i.e. the highest concentration used in our experiments,
resulted in intracellular lipid values close to levels before
cytokine treatment (Fig. 4). This suggests that the
cytokines suppress macrophage lipid turnover. We there-
fore proceeded to analyze whether IL-1β and TNF-α
affected mechanisms for lipid efflux and lipid metabolism
in macrophage foam cells.
Fatty acid efflux and triglyceride turn-over
THP-1 cells were incubated in presence or absence of lipo-
proteins and thereafter incubated with 0–5000 pg
cytokine/ml. Conditioned media after cytokine treatment
were analyzed for free fatty acid (FFA) content by colori-
metric analysis. After cytokine treatment, FFA levels were
3–4 times higher in conditioned media from triglyceride-
rich (VLDL treated) cells than in media from cholesterol-
rich (AgLDL treated) cells or in conditioned media from
cells incubated in absence of lipoproteins, however there
was no significant correlation between cytokine concen-
tration and FFA levels in conditioned media from any cell
type (data not shown). In an additional series of experi-
ment THP-1 cells were labelled with [9,10(n)-3H]-oleate
during lipoprotein uptake. Cells were then treated with
either of the two cytokines in lipoprotein and label free
media. Exposure of labelled and lipid loaded cells to TNF-
α significantly decreased the amount of fatty acid label
recovered in conditioned media (Fig. 5A and 5B).
Cytokine treatment of cells also resulted in increased
retention of labelled fatty acid in the intracellular triglyc-
eride (lipid droplet) fraction (Fig. 5C and 5D).
Acyl-Coenzyme A synthetase activity
Differentiated THP-1 cells were lipid loaded by incuba-
tion with VLDL, and then treated with IL-1β in lipoprotein
free media as described above. Cells were homogenized
and separated in sub-cellular fractions. Acyl-CoA syn-
thetase activity was assessed for five minutes in aliquots
Figure 3
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Lipid content of THP-1 macrophages incubated with TNF-α Figure 3
Lipid content of THP-1 macrophages incubated with 
TNF-α. Cells were differentiated for four days with PMA, 
and then incubated for 24 h in absence or presence of lipo-
proteins (50 μg/ml), rinsed with heparin and incubated with 
TNF-α in lipoprotein-free media for an additional 24 h. Intra-
cellular lipids were extracted and lipid values normalized to 
cell protein content. A. Triglyceride content of VLDL treated 
cells, B. Triglyceride content of control or AgLDL treated 
cells, C. Cholesterol content of cells. Data represents mean 
± SEM (n = 6) for a representative experiment repeated 
three times with cells from different donors. * = P < 0.05, ** 
= P < 0.01 compared to cells incubated in absence of TNF-α. 
Diamonds = control cells (no lipoprotein lipid loading), 
squares = AgLDL, triangles = VLDL.BMC Immunology 2008, 9:70 http://www.biomedcentral.com/1471-2172/9/70
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containing mitochondria or endoplasmic reticulum.
Enzymatic activity was affected by cytokine treatment in a
dose-dependent manner, where IL-1β stimulated acyl-
CoA synthetase activity of the endoplasmic reticulum and
suppressed enzyme activity in mitochondria, indicating
enhanced fatty acid esterification and decreased β-oxida-
tion in cytokine-stimulated cells (Fig 6).
Expression and secretion of apolipoprotein E
Primary human macrophages or THP-1 cells were incu-
bated in absence of lipoproteins, or with VLDL or AgLDL,
and then treated with IL-1β or TNF-α as in previous exper-
iments. Incubation with either cytokine did not result in
any consistent effects on apolipoprotein E (apoE) secre-
tion from cells (Fig. 7). Real-time PCR analysis did not
demonstrated any significant effects of either cytokine on
apoE mRNA levels in lipid loaded or control cells (data
not shown).
Discussion
Atherosclerosis is a disease accelerated by inflammation
and by plasma dyslipidemia, where the latter typically
include high levels of LDL and VLDL. In virtually all
eukaryotic cells intracellular lipid will accumulate in lipid
droplets when lipoprotein lipid uptake exceeds lipid deg-
radation and efflux. In atherosclerotic plaques, macro-
phage foam cell lipid droplets mainly accumulate
cholesterol ester [3]. Pro-inflammatory cytokines have
earlier been reported to increase intracellular cholesterol
levels in some cell types; IL-1β increases cholesterol accu-
mulation in mesengial cells by up-regulation of scavenger
receptors, by dysregulation of the LDL receptor, and by
inhibition of cholesterol efflux mediated by the ATP bind-
ing cassette transporter protein A1 (ABC-A1) [4].
Cytokines have also been reported to affect macrophage
lipid efflux in mouse J774 cells, where IL-1β or TNF-α
both decrease mRNA and protein levels of ABC-A1 [5]. Figure 4
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Lipid content of THP-1 macrophages incubated with IL-1β Figure 4
Lipid content of THP-1 macrophages incubated with 
IL-1β. Cells were differentiated for four days with PMA, and 
then incubated for 24 h in absence or presence of lipopro-
teins (50 μg/ml), rinsed with heparin and incubated with IL-
1β in lipoprotein-free media for an additional 24 h. Intracellu-
lar lipids were extracted and lipid values normalized to cell 
protein content. A. Triglyceride content of VLDL treated 
cells, B. Triglyceride content of control or AgLDL treated 
cells, C. Cholesterol content of cells. Data represents mean 
± SEM (n = 6) for a representative experiment repeated 
three times with cells from different donors. * = P < 0.05, ** 
= P < 0.01 compared to cells incubated in absence of IL-1β. 
Diamonds = control cells (no lipoprotein lipid loading), 
squares = AgLDL, triangles = VLDL.BMC Immunology 2008, 9:70 http://www.biomedcentral.com/1471-2172/9/70
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It is clear from our experiments that when THP-1 cells
were lipid loaded by incubation with lipoproteins and
then incubated in cytokine free media, the cells utilized
stored lipids (Fig. 4: the "0" points for individual dose-
response curves compared to respective intracellular lipid
value before incubation with IL-1β). Cytokine treatment
after lipoprotein lipid loading resulted in dose-dependent
retention of intracellular lipid. The results suggest that
increased cellular lipid content after incubation with the
pro-inflammatory cytokine is the result of decreased intra-
cellular lipid catabolism and/or efflux. However, we can-
not exclude that lipid content of cells after cytokine
treatment in part also may reflect affected lipid synthesis.
Such directs effects on lipid synthesis have been reported
for adipocytes, where TNF-α decreases de novo fatty acid
synthesis, whereas IL-1β increases it [6].
Macrophage foam cells lack pathways for cholesterol deg-
radation; excess lipid can only be removed from cells via
reverse cholesterol transport pathways. Excess cholesterol
is removed from macrophage foam cells as oxysterols, via
efflux to extra-cellular acceptor particles, or via endog-
Fatty acid efflux and triglyceride lipid label in cytokine treated THP-1 cells Figure 5
Fatty acid efflux and triglyceride lipid label in cytokine treated THP-1 cells. Cells were differentiated for four days, 
then incubated for 24 h with [9,10(n)-3H]-oleate pre-incubated with lipoproteins (50 μg/ml) or added directly to cells (1 μCi/
well). After removing non-attached lipids with a heparin rinse, cells were incubated in lipoprotein-free media for an additional 
24 h with 0, 500, or 5000 pg/ml of respective cytokine. Cell lipids were extracted and lipid extracts separated by thin layer 
chromatography. Label was quantified in intracellular triglyceride fractions and conditioned media. A. Fatty acid label efflux nor-
malized to intracellular triglyceride label in IL-1β treated cells, B. Fatty acid label efflux normalized to intracellular triglyceride 
label in TNF-α treated cells, C. Fatty acid label in intracellular triglyceride fractions from IL-1β treated cells, D. Fatty acid label 
in intracellular triglyceride fractions from TNF-α treated cells. Data represents mean ± SD (n = 6) for a representative experi-
ment repeated three times. * = P < 0.05, ** = P < 0.01, *** = P < 0.001. Diamonds = control cells (no lipoprotein lipid loading), 
squares = AgLDL, triangles = VLDL.
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enous production of apoE leading to formation of LpE
particles that mediate cholesterol removal from human
monocyte-derived macrophages in absence of serum or
exogenous acceptor particles [7,8]. Cytokine treatment
may directly affect apoE production; long-term (3 days)
treatment with TNF-α stimulates human monocyte (but
not macrophage) apoE mRNA expression and protein lev-
els in vitro [9]. This effect may be species-specific, as 2 days
of incubation with TNF-α or IL-1β decreased de novo syn-
thesis of apoE secretion in mouse peritoneal macrophages
to approximately half of the level in control cells [10].
Neither cytokine exerted any consistent effect on apoE
secretion from control or lipid-filled cells. Our experi-
ments were performed in absence of extra-cellular accep-
tor particles, as we aimed to analyze cytokine effects on
endogenous macrophage lipid efflux pathways only.
Additional experiments using the same model systems as
above in presence of exogenous apoA-I or HDL particles
will shed further light on whether cytokine treatment also
affect lipid efflux pathways involving ABC transporters.
Treatment of macrophage foam cells with IL-1β or TNF-α
may decrease overall foam cell lipid efflux capacity,
although our data on efflux of labelled fatty acids did not
demonstrate cytokine effects strong enough to account for
the entire effect on intracellular lipid retention. TNF-α
(but not IL-1β) decreased efflux of labelled fatty acid from
cells, and both cytokines showed trends towards increas-
ing the amount of fatty acid label retained in the intracel-
lular triglyceride fraction after lipid loading and cytokine
treatment. These data indicate that cytokine treatment
may impede foam cell lipid droplet turnover.
An interesting observation is that regardless of method of
lipid loading cytokine effects on neutral lipid turnover
appeared to be stronger or more pronounced for triglycer-
ides than for cholesterol ester. Foam cell lipid droplet
turnover of triglycerides has been reported to be three to
four times faster than that of cholesterol esters [11]. It is
likely that the effects of IL-1β and TNF-α are partially
mediated by cytokine effects on enzymatic activity of acyl-
CoA synthetase, a key point for fatty acid oxidation but
also for fatty acid esterification and storage in triglycer-
ides, cholesterol ester, and phospholipids. Enzymatic
activity depends not only on protein levels or substrate
availability but also on intracellular location, as the same
enzyme activates fatty acids for catabolic β-oxidation in
mitochondria as for anabolic esterification on the endo-
plasmic reticulum. For that reason, we chose to analyze
acyl-CoA synthetase activity in different subcellular frac-
tions rather than in whole cell homogenates.
It has to be pointed out that Figure 6 illustrates ACS
enzyme activity during five minutes of incubation only.
The short incubation time of the ACS assay is necessary for
a linear dose response ratio between enzyme activity and
production of labelled product. The effects of IL-1β and
TNF-α on total intracellular triglyceride and cholesterol
content illustrated in Figures 1, 2, 3, 4 are the result of
incubations with respective cytokine for 24 h. Therefore,
although the cytokine effect on ACS activity during short
term incubation is minor, it is likely that the combined
decrease in activation of fatty acids for subsequent β-oxi-
dation and increase in activation of fatty acids for esterifi-
cation will result in major accumulation of intracellular
lipids over time.
It can be argued that cytokine concentrations used in our
experiments are high compared to what is found in vivo.
Serum concentrations of IL-1β and TNF-α are typically in
the low pg/ml range, with increases in serum concentra-
tions found in post-infarction and diabetic patient (values
ranging between 10–25 pg/ml). It is well documented
that IL-1β and TNF-α expression is strongly increased in
atherosclerotic plaques compared with surrounding tis-
sues, but this is typically analyzed with immunohisto-
chemical methods or with PCR analysis of mRNA
expression [12,13]. Attempts have been made to analyze
plaque cytokine production directly, such as analyses of
TNF-α secretion in endotoxin-stimulated culture of
explanted human atherosclerotic plaque tissue [14], with
final cytokine concentration in conditioned media reach-
Acyl-CoA activity in triglyceride-loaded THP-1 cells treated  with IL-1β Figure 6
Acyl-CoA activity in triglyceride-loaded THP-1 cells 
treated with IL-1β. Cells were differentiated, incubated for 
24 h with VLDL (50 μg/ml), and then incubated in lipopro-
tein-free media for an additional 24 h with IL-1β. Cells were 
homogenized and intracellular fractions isolated by differen-
tial centrifugation. Enzymatic activity during a five minutes 
incubation was assayed in fractions containing mitochondria 
(open circles) or endoplasmic reticulum (closed circles). 
Data represents mean ± SEM, n = 6, for a representative 
experiment repeated three times. * = P < 0.05, ** = P < 0.01.
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ing 200 pg/ml. It is likely that concentrations of cytokines
in the vicinity of cells in atherosclerotic plaques are several
degrees of magnitude higher than serum concentrations
or concentrations in tissue culture, making the higher
concentrations used in the current experiment possible in
vivo.
Conclusion
Our data suggests that IL-1β and TNF-α may share a pre-
viously unknown effect on macrophage foam cells, result-
ing in retention of neutral lipids by a combination of
decreased lipid efflux, decreased β-oxidation substrate
availability, and stimulated fatty acid esterification. If
such mechanisms are active in vivo, the high neutral lipid
content of cytokine-treated cells may contribute to athero-
sclerotic development and even accelerate development
of unstable lipid-rich atherosclerotic plaques.
Methods
Lipoprotein isolation
Lipoproteins were prepared by differential ultra centrifu-
gation of fresh plasma from healthy donors [15]. Lipopro-
teins were mixed with sucrose (10%, w/v) and EDTA (4.8
mM, pH = 7.4), frozen immediately and stored at -80°C
[16]. Just before use, lipoproteins were desalted and lipo-
protein concentration determined with BCA (bicin-
Apolipoprotein E secretion from lipid loaded and cytokine treated cells Figure 7
Apolipoprotein E secretion from lipid loaded and cytokine treated cells. Cells were differentiated for four days, lipid 
loaded for 24 h, then treated with respective cytokine in lipoprotein-free media for an additional 24 h. ApoE content was 
measured in conditioned media after cytokine treatment. A. ApoE secreted from primary human macrophages after lipid load-
ing and treatment with IL-1β. B. ApoE secreted from primary human macrophages after lipid loading and treatment with TNF-
α. C. ApoE secreted from THP-1 cells after lipid loading and treatment with IL-1β. D. ApoE secreted from THP-1 cells after 
lipid loading and treatment with TNF-α. Data represents mean ± SEM (n = 6) for a representative experiment repeated three 
times. * = P < 0.05, ** = P < 0.01 compared to cells incubated in absence of TNF-α. Diamonds = control cells (no lipoprotein 
lipid loading), squares = AgLDL, triangles = VLDL.
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choninic acid) protein assay reagent (Pierce). AgLDL was
prepared by vortex for 3 min [17].
Isolation and culture of primary human monocytes/
macrophages
Human peripheral blood monocytes were isolated from
buffy coats obtained from healthy blood donors as previ-
ously described [18]. Cells were differentiated for four
days in macrophage-serum free media with granulocyte
macrophage-colony stimulating factor (GM-CSF, 1 ng/
ml) [19]. After this, fresh GM-CSF free media was added
to each plate. Cells were incubated for 24 h with or with-
out addition of AgLDL or VLDL, both at 50 μg protein/ml.
After lipid loading cells were washed with a heparin solu-
tion (20 U/ml in PBS) in order to remove lipoproteins
attached to cell surfaces. Finally, cells were incubated for
an additional 24 h in absence of lipoproteins with addi-
tion of IL-1β or TNF-α (0–5000 ng/ml, cell culture tested,
BD Biosciences), as specified in the Result section.
THP-1 cell culture
Human THP-1 monocytes were differentiated with PMA
for four days in accordance with instructions from ECACC
(European collection of cell cultures). After this, fresh
serum and PMA free media supplemented with BSA (1%)
was added to cells. As for primary cells, THP-1 cells were
incubated for 24 h with or without addition of AgLDL or
VLDL, both at 50 μg protein/ml. After lipid loading, cells
were subjected to the same heparin rinse as primary cells,
and then incubated for an additional 24 h in serum, lipo-
protein, and PMA free media with addition of 1% BSA
and IL-1β or TNF-α (0–5000 ng/ml), as specified in the
Result section.
Cell viability
Lipoprotein and cytokine treatments at concentrations
used in the experiments were not toxic to either cell type,
as judged by the methylthiazoletetrazolium assay (Sigma)
or leakage of lactate dehydrogenase (Sigma assay) to cell
culture media.
Cell lipid and protein analyses
Cell lipids were extracted with hexane:isopropanol (3:2 +
0.005% butylated hydroxytoluene). Lipid analyses (trig-
lycerides and total cholesterol) were performed with
colorimetric assays (Wako). After lipid extraction, residual
cell proteins were dissolved in 0.3 M NaOH (aq) and cell
lysates used for cell protein analyses with BCA protein
assay reagent.
Analysis of free fatty acid content
FFA content of conditioned cell culture media was ana-
lyzed by a colorimetric method according to the manufac-
turer's instructions (Wako NEFA C ACS-ACOD) using a
0–1 mM serial dilution of stabilized oleate as standard,
prepared fresh for each analysis.
Fatty acid turnover
Differentiated THP-1 cells were incubated for 24 h in
serum and PMA free media in absence or presence of lipo-
protein (50 μg/ml). Labelled fatty acid ([9,10(n)-3H]-
oleate in ethanol, 1 μCi/sample) was added either to lipo-
proteins before addition to cells, or directly to plates of
control cells incubated in absence of lipoproteins. Con-
trol experiments demonstrated that the lipid label mainly
resided in triglyceride, cholesterol ester, and phosphatidyl
choline fractions of cells after initial lipoprotein uptake
and fatty acid labelling of cells, with only low levels of
label recovered in the intracellular FFA fraction. After
labelling, cells were rinsed with a heparin solution (20 IU/
ml in PBS) and incubated for an additional 24 h in fresh
serum, lipoprotein, and PMA free media in presence of 0–
5000 pg IL-1β or TNF-α/ml. Efflux of labelled fatty acids
and fatty acid degradation products to conditioned media
was analyzed by liquid scintillation counting after centrif-
ugation for 5 min at 1000 rpm (to remove floating cells
and cell debris). At termination of experiments, cells were
rinsed with the heparin solution and cell lipids extracted
as described above. Lipid extracts were separated in polar
and neutral lipid classes by high performance thin layer
chromatography [20]. Triglyceride fractions were
extracted from silica with ethanol and analyzed by liquid
scintillation counting.
Acyl-Coenzyme A synthetase activity
Acyl-CoA synthetase activity was assayed according to
Tanaka et al [21]. Assay conditions were optimized for a
linear response between enzyme activity and accumula-
tion of labelled product. Briefly, treated and rinsed THP-1
cells were carefully homogenized in 0.25 M sucrose with
handheld miniature homogenizers. Nuclear fractions
were removed by repeated homogenization and centrifu-
gation for 10 min at 600g. The mitochondrial fraction was
separated by centrifugation for 20 min at 13000g. Mito-
chondria and the remaining fraction (containing the
endoplasmic reticulum) were incubated for five minutes
with [1-14C]-palmitate (0.2 μCi/sample) in presence of
CoA and ATP. After termination of experiment the
remaining labelled fatty acid was separated from labelled
acyl-CoA by repeated extractions with n-heptane. Enzy-
matic activity of acyl-CoA synthetase was finally assessed
by scintillation counting of the aqueous fraction, which
after n-heptane extraction contains labelled palmitate-
CoA only.
Cytokine ELISA
After incubation of cells, protease inhibitor (phenyl
methyl sulfonyl fluoride saturated in isopropanol) was
added to conditioned media and samples were spun forBMC Immunology 2008, 9:70 http://www.biomedcentral.com/1471-2172/9/70
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10 min at 2500 rpm in order to remove debris. Samples
were either analysed directly or divided in aliquots and
stored at -20°C until analysis. Concentrations of secreted
endogenous IL-1β and transforming growth factor-β
(TGF-β) were analyzed by commercial ELISA sets (R&D
systems).
Apolipoprotein E ELISA
Hi-bond ELISA plates were incubated over night at 4°C
with monoclonal IgG1 mouse anti-human apoE (Santa
Cruz Biotechnology) diluted 1:200 in PBS. Plates were
blocked at room temperature for 2 h with 4% BSA in 0.15
M PBS, and then incubated for 2 h at room temperature
with samples in duplicates. Human apoE (purified from
human plasma VLDL, 0–500 ng/ml, Calbiochem), in
non-conditioned serum-free cell culture medum was used
as standard. After this, plates were incubated with polyclo-
nal goat anti-human apoE (Calbiochem) diluted 1:8000
in 0.5 M PBS with 0.2% Tween-20 (PBS+T) and 4% BSA
for 2 h in room temperature, and then over night at 4°C.
Finally, plates were incubated for 2 h at room temperature
with biotinylated horse anti-goat IgG (Immunkemi)
diluted 1:5000 in PBS+T with 4% BSA, and then for an
additional 2 h at room temperature with horse-radish per-
oxidase conjugated avidin diluted 1:5000 in PBS+T with
4% BSA. ApoE concentrations were quantified with
tetramethylbenzidine substrate reagent at 450 nm with
570 nm as reference wavelength.
ApoE PCR
Total RNA was isolated using RNeasy micro kit following
the manufacturer's protocol (Qiagen). RNA was treated
with DNAse (deoxyribonuclease I, Sigma) and cDNA syn-
thesis performed according to standard protocol [22].
Primer sequences for human apoE were: forward primer
ACTGAGGGCGCTGATGGA, reverse primer GGTCAGTT-
GTTCCTCCAGTTCC. Real-time PCR was performed using
SYBR Green reagent on a Perkin-Elmer ABI Prism 7700
with VLDL-loaded THP-1 cells used for preparation of
standard curve and 18S as internal control.
Statistical analyses
Data are represented as mean ± SEM. Statistical analysis
was performed by Mann-Whitney test using SPSS 12.0.1
software. P-values < 0.05 were considered statistically sig-
nificant.
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